Introduction

41
The complement cascade is an integral component of our innate immune response and 42 a first line of defense against bacterial infections. Various components of the 43 complement cascade are constantly surveying for invading pathogens or debris, and 6 each genotype. Targeted primers confirmed the presence of human CR2 and CR1 in the 137 spleen and the absence of mouse Cr2 (Fig. 4A-E) . For CR1, primers designed for CR1 138 targeted both exon 2 and a region spanning exons 4 and 5. This strategy enabled 139 identification of B6.CR2CR1 KO/KO mice that produced a transcript containing only the first 140 two exons and not exons 4 and 5. As expected, Crry transcript, a mouse-specific gene 141 that lies downstream of Cr2, was seen in all samples (Fig. 4E) .
143
To assess expression of human CR2 and CR1 protein isoforms, western blotting was 144 used. Samples from B6.CR2CR1 long/long and B6.CR2CR1 short/short mice showed bands at 145 their predicted sizes (273 kDa and 223 kDa respectively) (Figs. 4F, S1 and S2).
146
Interestingly, samples from B6.CR2CR1 long/long mice appear to have a lower level of 147 protein expression compared to samples from B6.CR2CR1 short/short mice. Samples from 148 B6 mice were used as a negative control and to determine cross reactivity of antibodies.
149
For CR2, all mice showed a single band at 148 kDa, with the exception of B6 mice 150 where a second 190kDa band was seen (Fig. S2) . This is to be expected as the mouse 
177
'negative regulation of histone acetylation' was significant, suggesting that expression of 178 CR1 in B6.CR2CR1 long/long mice may affect some epigenetic signatures when compared 179 to B6 controls. For molecular function (MF), GO terms showed changes relating to 180 binding, such as 'haptoglobin binding', 'chloride ion binding', 'organic acid binding' and 181 'copper ion binding', indicating that the CR1 long gene may be playing a role in intracellular 182 binding ( Fig. 5C) . None of these pathways or GO terms were enriched in the DE genes 183 comparing samples from B6.CR2CR1 short/short mice or B6.CR2CR1 KO/KO to B6.
185
The number of DE genes was greater in the brain when compared to the spleen (Fig.   186   5D ). There were 183 DE genes identified by comparing B6.CR2CR1 long/long mice to B6 187 (Table S4) , 58 DE when comparing B6.CR2CR1 short/short with B6 (Table S5) , and only 5 188 DE genes between B6.CR1 KO/KO and B6 (Table S6 ). This trend reflects the results seen 189 in the spleen, indicating that expression of CR1 long in mice had the greatest effect on 190 gene expression in the brain compared with mice expressing either CR1 short or CR1 KO .
191
CR1 long was expressed at a low level in the brain (0.5 cpm on average), while no 192 transcripts were detected for CR1 short . 
212
Analysis' was performed in IPA. This function predicts increases or decreases in 213 downstream biological activities using the direction of change of the genes in each DE 214 gene list. In the spleen, multiple functional terms were predicted to be increased with the 215 DE genes comparing B6.CR2CR1 long/long with B6. These could be generally classified as 216 being related to regulation of hematopoietic cell number and were predicted to be 217 activated ( Fig. 6A) . Two terms considered significant were 'quantity of erythroid 218 precursor cells' and 'quantity of myeloid cells'. Interestingly, genes associated with these 219 terms were generally downregulated, including Hba-a1 (-39.74 fold), Hba-a2 (-19.25 220 fold) and Hbb-bs (-20 .00 fold) which all encode for hemoglobin subunits (Fig. 6B,C) .
221
These data suggest that there is an effect of the CR1 long allele on hematopoietic quantity 222 in the spleen. These functional consequences were not associated with DE genes when 223 comparing samples from either B6.CR2CR1 short/short or B6.CR2CR1 KO/KO with B6.
225
In the brain samples, functional consequences associated with DE genes comparing 226 B6.CR2CR1 long/long with B6 samples included 'cellular infiltration by leukocytes' and 227 'infiltration by neutrophils' (p<0.05, Fig. 6D ). DE genes associated with these terms were 228 generally upregulated including Hyal1 (14.78 fold), Tlr9 (3.44 fold) and Cd276 (4.59 fold) 229 ( Fig. 6E,F) . HYAL1, a lysosomal hyaluronidase that degrades hyaluronan (a major 230 constituent of extracellular matrix), has been shown to be involved in cell proliferation, (Chapoval et al., 2001; Coyle and Gutierrez-Ramos, 2001) . Collectively, these data 236 predict CR1 long and CR1 short in the brain will differentially modulate immune-like cells 237 9 such as resident microglia or the infiltration and functioning of peripherally derived 238 immune cells -functional differences that may alter risk for disease such as Alzheimer's 239 disease.
10
Discussion
241
Here, we present a new mouse model that may be of value to study of an array of 242 human diseases including Alzheimer's disease (Biffi et al., 2010; Brouwers et al., 2012;  243 Carrasquillo et al., 2010; Corneveaux et al., 2010; Hazrati et al., 2012; Jun et al., 2010;  244 Keenan et al., 2012; Lambert et al., 2009; Van Cauwenberghe et al., 2013) , Systemic
245
Lupus Erythematosus (Birmingham et al., 2006; Corvetta et al., 1991; Holme et al., 246 1986; Katyal et al., 2003; Khera and Das, 2009; Marquart et al., 1995; Miyakawa et al., 247 1981; Moulds et al., 1996; Richardson et al., 1990; Ross et al., 1985; Walport et al., 248 1985; Wilson et al., 1986; Wu et al., 2007) and infections such as malaria (Birmingham 249 et al., 2003; Khera and Das, 2009; Thomas et al., 2005; Xiang et al., 1999) . This model 250 is the first to express both human proteins CR1 and CR2 in the mouse. We show that 251 the humanized B6.CR2CR1 strain expresses CR2 in place of mouse Cr2 and is capable 252 of expressing two different isoforms of human CR1 -a long form and a short form. CR1 253 and CR2 are important regulators of the complement cascade but their specific roles in 254 human diseases have been difficult to study in models due to the species differences 255 between humans and mice ( Fig. 1) (Davoust et al., 1999; Killick et al., 2013; Maier et al., 256 2008; Manickam et al., 2010; Marchbank et al., 2002; Pappworth et al., 2012; Prodeus et 257 al., 1998; Ramaglia et al., 2012; Repik et al., 2005; Wu et al., 2002) .
259
We anticipate this mouse model will provide an important resource for elucidating the 260 functions of CR1 and CR2 in human diseases -however further work is required to 261 assess its full potential. First, it will be necessary to validate that human forms of CR1 262 and CR2 regulate the mouse complement system in a similar fashion to those seen in 263 human studies. To do this, both CR2 and CR1 (long and short forms) will need to be 264 tested for their ability to bind mouse C3b, C4b and C1q, three central components of the 265 cascade. Second, testing existing and new antibodies that specifically recognize the 266 human forms of CR1 and CR2 expressed in this mouse is required to confirm tissue and 267 cellular distribution patterns in health and disease. Commonly used mouse anti-human 268 CR1 monoclonal antibodies were tested but were unsatisfactory in the B6.CR2CR1 273 strain as well as in strains deficient in mouse CR2 protein (B6.Cr2 KO ) and mouse CRRY protein (B6.Crry KO ) will eliminate the antibody specificity issue and potential for cross-275 reactivity due to similarities between these homologous genes. Establishing the gene 276 expression patterns of human CR2 and CR1 in specific cell types, particularly in the 277 spleen, brain and blood, will be necessary. Human CR1 is broadly expressed, albeit in 278 varying quantities, on the plasma membranes of blood derived cells, including 279 erythrocytes, eosinophil, monocytes/macrophages, B-lymphocytes, dendritic cells and a 280 sub-set of CD4+ T-cells (Danielsson et al., 1994; Fang et al., 1998; Merle et al., 2015a;  281 Merle et al., 2015b; Pascual et al., 1993; Rodgaard et al., 1991; Rodgaard et al., 1995;  Alzheimer's disease is incompletely understood. One study (Hazrati et al., 2012) 307 identified the risk for Alzheimer's disease is most likely associated with the B allele of 12 CR1 (CR1-B, equivalent to CR1 long in this study), with one copy of CR1-B carrying a 1.8x 309 higher risk of disease over the CR1-A/A allele (equivalent to CR1 short in this study) and a 310 faster rate of cognitive decline. These observations make determining the function of 311 CR1 specifically in the brain of key importance to fully elucidate its role in Alzheimer's 312 disease. Differences in neuronal morphology and distribution between CR1-A/A and 313 CR1-A/B carriers were also reported, the former having a more filiform neuronal 314 structure with CR1 expression that associated with the endoplasmic reticulum, whereas 315 the latter had a more vesicular-like pattern of CR1 expression associating with In summary, the ability to more closely study CR1 and CR2 in a model system such as 344 the mouse will facilitate our understanding of the role that these receptors, and the 345 complement cascade more generally, play in a wide variety of diseases that show a 346 strong immune component. A more complete understanding of the complement 347 cascade, and its regulators, will lead to more targeted and personalized therapeutics for 
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Chimeric mice from two targeted B6 ES cell lines, 5H4 and 5E2, were bred to B6 Tyr mice 381 ( Fig. 2) . From these, black pups were pursued for further breeding as a consequence of 382 B6 ES cells being targeted initially. Mice determined positive through genotyping for the 383 construct were then bred to B6 to confirm germline transmission by genotyping (Fig. 2) .
384
After germline transmission was confirmed, male mice from each line were sent for 385 sperm cryopreservation, with the Neomycin (Neo) cassette intact, and are available 386 upon request. Mice from the 5H4 line were used throughout this study.
388
Developing the CR1 allelic series
389
The initial stage of developing the allelic series was to remove the Neo cassette within 390 intron 19 of CR2. To achieve this, mice derived from the 5H4 ES cell line were bred to 391 B6.129S4-Gt(ROSA)26Sortm3(phiC31*)Sor/J (B6.ROSA-Phi, Jax #7743) mice, to target 392 the attB-attP region surrounding Neo (Fig. 2) . Mice negative for Neo were intercrossed 393 to establish B6.CR2CR1 long/long strain ( Fig. 1 and 2) . For CR1 short , B6.CR2CR1 long/+ mice 394 were crossed to B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ (B6.ROSA-Flp, Jax 395 #9086) mice. The Flp recombinase is ubiquitously expressed and targets the removal of 396 LHR1' (Fig. 1) encoded by exons 13-20 (via the flanking FRT sites in synthetic introns 397 12 and 20; Fig. 2) . Mice carrying CR1 short (B6.CR2CR1 short/+ ) were intercrossed to 398 establish the B6.CR2CR1 short/short strain ( Figs. 1 and 2) . Finally, for CR1 KO ,
399
B6.CR2CR1 long/+ mice were crossed to B6.Cg-Tg(Sox2-cre)1Amc/J (Sox2-cre Jax 400 #8454). In this strain, Cre recombinase is ubiquitously expressed and excises the 401 targeted region using the LoxP sites, located within introns 3 and 20, to create a null 402 allele (knockout, KO). Female B6.Sox2-cre mice were bred to male B6.CR2CR1 long/+ 403 mice, as Cre recombinase is active without necessarily needing to be inherited. Mice 404 carrying CR1 KO (B6.CR2CR1 KO/+ ) mice were intercrossed to establish the 405 B6.CR2CR1 KO/KO strain (Figs. 1 and 2) .
407
Genotyping 408 PCR assays for genotyping were as follows:
409
For mouse Cr2 or human CR2 (Fig. 3) : Common primer forward primer: 5' - 
16
For CR1 long (Fig. 3) : Forward 5' -GTACTACGGGAGGCCATTCT -3' and Reverse 5' -418 TGGCTTGGGGTACGCTC -3' with a product size of 708bp at an annealing 419 temperature of 58.1°C.
420
For CR1 KO (Fig. 3) 
424
For CR1 short (Fig. 3) , forward primer from the KO allele with the Reverse primer 5' - To determine protein presence and the size difference between the CR1 long and CR1 short , 484 alleles, 6% SDS PAGE gels were hand cast. Protein was diluted to 80μg of total protein 485 with 2x Laemmli buffer (BioRad). Samples were denatured at 95°C for 5min and loaded 486 onto the gel. Gels were run for 1hr at 150V and transferred to nitrocellulose membrane 487 via the iBlot for 13mins. Blots were incubated at room temperature for 1 hour (hr) with 488 blocking solution (5% skimmed milk powder block in 0.1% PBS-Tween), washed with 489 0.1% PBS-Tween for three 15min incubations and then incubated with rabbit-anti-human 490 CR1 (also known as CD35; Abcam #ab126737, 1:100) for 48hrs in 0.1% PBS-Tween on 491 an orbital shaker at +4°C. Blots were washed three times in 0.1% PBS-Tween and 492 incubated with the appropriate secondary (Anti-Rabbit IgG HRP 1: 50,000) for 1.5hrs at 493 RT. Blots were then washed an additional three times and detection was carried out 494 using ECL detection regents (GE Healthcare). When required, blots were stripped by 495 treatment with 0.25% sodium azide for 2hrs at RT and washed thoroughly in 0.1% PBS-
496
Tween. Blots were re-blocked and re-probed with mouse anti-CD21 (anti-human CR2;
497
Abcam #ab54253, 1:100) in 0.1% PBS-Tween overnight at +4°C. Blots were washed 498 and incubated in the appropriate secondary antibody (Anti-Mouse IgG HRP 1:40,000), 499 washed and detected. Finally, blots were treated with 0.25% sodium azide and probed 500 with a loading control, anti-Vinculin (1:10,000) in 0.1% PBS-Tween overnight at +4°C, 501 washed three times, incubated with the appropriate secondary antibody (Anti-Rabbit 502 HRP 1:50,000) for 1hr at RT, washed and detected.
504
Transcriptional profiling 505 RNA isolation, library preparation and sequencing: RNA was isolated from tissue using 506 the MagMAX mirVana Total RNA Isolation Kit (ThermoFisher) and the KingFisher Flex 
524
Sequence Alignment & Statistical Analysis Methods: FASTQ files were trimmed using 525 Trimmomatic v0.33 which removed adapters and sequences with more than 2 526 mismatches, a quality score < 30 for PE palindrome reads, or a quality score of < 10 for 527 a match between any adapter sequence against a read. A sliding window of 4 bases 528 was used with a required (average) minimum quality score threshold of 15. The leading 529 and trailing minimum quality score thresholds were set to 3 to keep a base. Reads had 530 to be 36 bases or greater in length. Sequence alignment was completed using the Mus 531 musculus Ensembl v82 reference genome in addition to three custom references based 532 on that genome. Samples from both brain and spleen tissue were edited to include one 533 (or none) of three human transgenes: CR1 long , CR1 short , or CR1 KO. Each of the three 534 human transgene sequences was appended to the Mus musculus reference genome 535 individually; thus, three additional reference genomes were created to quantitate gene 536 and isoform expression levels using RSEM v1.2.19. B6 samples were evaluated with 537 the base Mus musculus reference genome. RSEM leveraged Bowtie2 alignment with 538 strand-specific and paired-end parameters. The resulting gene/transcript (feature) count 539 data were processed using edgeR v3.14.0 (R v3.3.1). For each of the four datasets 540 (brain and spleen, gene and transcript), feature differential expression was evaluated in 541 three pairwise comparisons per sex: 1.) CR1 long vs. B6, 2.) CR1 short vs. B6, and 3.) CR1 KO 542 vs. B6. There were no differences between male vs female for each of the three 543 comparisons, so samples were pooled by genotype to increase the quantity from three 544 (three per sex) to six (pooled sexes). Any feature that did not have at least 1 read per 545 million for at least 2 samples in either sets of samples evaluated in the pairwise 546 comparison was excluded from the differential expression analysis. The Cox-Reid 547 profile-adjusted likelihood method was used to derive tagwise dispersion estimates 548 based on a trended dispersion estimate. The GLM likelihood ratio test was used to 549 20 evaluate differential expression in pairwise comparisons between sample groups. The
550
Benjamini and Hochberg's algorithm was used to control the false discovery rate (FDR).
551
Features with an FDR-adjusted p-value < 0.05 were declared statistically significant. number of genes in the pathway associated with each term (see Table S7 ). 
